OncoMatch/Clinical Trials/NCT05013892
NTS-WBRT in Brain Metastases
Is NCT05013892 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Memantine for brain metastases.
Treatment: Memantine — This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: whole brain radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05013892 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior whole brain radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify